The clinical significance of CD34 expression and BRAF mutation was investigated in a recent publication aiming to study the relationship between biomolecular markers and clinical-pathological features in 22 cases of low-grade epilepsy-associated neuroepithelial tumors [8]. The gene discussed is BRAF; the disease is neuroepithelial neoplasm.